Proliferation and the advantage of longer-lived radionuclides in radioimmunotherapy

Medical Physics

Volumn 25, Issue 1, 1998, Pages 37-42

  Howell, Roger W ^a   Goddu, S Murty ^a   Rao, Dandamudi V ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Dosimetry; Linear quadratic model; Proliferation; Radioimmunotherapy

Indexed keywords

DOSIMETRY; RADIOTHERAPY; TUMORS;

BIOLOGICALLY EFFECTIVE DOSE; DELETERIOUS EFFECTS; LINEAR-QUADRATIC MODELS; PROLIFERATION; RADIOIMMUNOTHERAPY; SHORT-LIVED RADIONUCLIDES; THERAPEUTIC EFFECTS; THERAPEUTIC EFFICACY;

RADIOISOTOPES;

INDIUM 114M; PHOSPHORUS 32; RADIOISOTOPE; UNCLASSIFIED DRUG; YTTRIUM 90; YTTRIUM 91;

ARTICLE; BONE MARROW; CALCULATION; CONTROLLED STUDY; LIFESPAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; TUMOR GROWTH;

EID: 0031883874     PISSN: 00942405     EISSN: None     Source Type: Journal    
DOI: 10.1118/1.598171     Document Type: Article

References (25)

1. D. J. Macey, S. J. Denardo, G. L. Denardo, J. K. Goodnight, and M. W. Unger, "Uptake of indium-111 labeled monoclonal antibody ZME-018 as a function of tumor size in a patient with melanoma," Am. J. Physiol. Imag. 3, 1-6 (1988).
2. S. E. Order, J. L. Klein, D. Ettinger, P. Alderson, S. Siegelman, and P. Leichner, "Phase I-II study of radiolabelled antibody integrated in the treatment of primary hepatic malignancies," Int. J. Radiat. Oncol., Biol., Phys. 6, 703-710 (1980).
3. H. B. Breitz, P. L. Weiden, J.-L. Vanderheyden, J W. Applebaum, M. J. Björn, M. F Fer, S. B. Wolf, B. A. Ratliff, C. A. Seiler, D C Foisie, D. R. Fisher, R. W. Schroff, A. R. Fritzberg, and P. G. Abrams, "Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: Results of phase I trials," J. Nucl. Med. 33, 1099-1112 (1992).
4. D. M. Goldenberg, J. Horowitz, R. M. Sharkey, T. C. Hall, S Murthy, H. Goldenberg, R. E. Lee, R. Stein, J. A Siegal, D. O. Izon, K. Burger, L. C Swayne, E. Belisle, H. J. Hansen, and C M. Pinsky, "Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody," J. Clin. Oncol. 9, 548-564 (1991).
5. J. F Fowler, "Radiobiological aspects of low dose rates in radioimmunotherapy," Int. J. Radiat. Oncol., Biol., Phys. 18, 1261-1269 (1990).
6. V K. Langmuir, J. F Fowler, S. J. Knox, B. W. Wessels, R. M. Sutherland, and J. Y C. Wong, "Radiobiology of radiolabeled antibody therapy as applied to tumor dosimetry," Med. Phys. 20, Pt. 2, 601-610 (1993).
7. D. V Rao, and R. W. Howell, "Time dose fractionation in radioimmunotherapy Implications for selecting radionuclides," J. Nucl. Med. 34, 1801-1810 (1993).
8. R. W Howell, S. M. Goddu, and D. V Rao, "Application of the linear-quadratic model to radioimmunotherapy: Further support for the advantage of longer-lived radionuclides," J. Nucl Med. 35, 1861-1869 (1994).
9. G. W. Barendsen, "Dose fractionation, dose rate and iso-effect relationships for normal tissue responses." Int. J. Radiat. Oncol., Biol., Phys. 8, 1981-1997 (1982).
10. R. G. Dale, "The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy," Br. J. Radiol. 58, 515-528 (1985).
11. J. F Fowler, "The linear-quadratic formula and progress in fractionated radiotherapy," Br J. Radiol. 62, 679-694 (1989).
12. R. W. Howell, S. M. Goddu, and D. V. Rao, "Design and performance characteristics of an experimental Cs-137 irradiator to simulate internal rudionuclide dose rate patterns," J. Nucl. Med. 38, 727-731 (1997).
13. D. V Rao, and R. W. Howell, "On the modeling of the tumor uptake to determine the time-dose-fractionation (TDF) effect in radioimmunotherapy (reply to letter)," J. Nucl. Med. 35, 1562-1564 (1994).
14. A. Liu, L. E. Williams, A. J. Demidecki, A. A. Raubitschek, and J. Y. C. Wong, "On the modeling of the tumor uptake to determine the time-dose-fractionation (TDF) effect in radioimmunotherapy (letter)," J. Nucl Med. 35, 1561-1562 (1994)
15. R. G. Dale, "Radiobiological assessment of permanent implants using tumour repopulation factors in the linear-quadratic model," Br. J. Radiol 62, 241-244 (1989).
16. C. C. Ling, "Permanent implants using Au-198, Pd-103 and I-125: Radiobiological considerations based on the linear quadratic model," Int. J. Radiat. Oncol., Biol., Phys. 23, 81-87 (1992).
17. B. W Wessels, and R. D. Rogus, "Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies," Med. Phys. 11, 638-645 (1984).
18. C.-T. Wu, and L. G. Lajtha, "Haemopoietic stem-cell kinetics during continuous irradiation," Int J. Radiat. Biol. 27, 41-50 (1975).
19. J. Y. C. Wong, L. E. Williams, A. J. Demidecki, B. W. Wessels, and X. W. Yan, "Radiobiologic studies comparing yttrium-90 irradiation and external beam irradiation in vitro," Int. J. Radiat. Oncol., Biol., Phys. 20, 715-722 (1991).
20. J. L. Humm, and L. M Cobb, "Nonuniformity of tumor dose in radioimmunotherapy," J. Nucl. Med. 31, 75-83 (1990).
21. C. S. Kwok, W. V. Prestwich, and B. C. Wilson, "Calculation of radiation doses for nonuniformly distributed beta and gamma radionuclides in soft tissue," Med. Phys. 12, 405-412 (1985).
22. R. W. Howell, D. V. Rao, and K. S. R. Sastry, "Macroscopic dosimetry for radioimmunotherapy: Nonuniform activity distributions in solid tumors," Med. Phys 16, 66-74 (1989)
23. R. G. Dale, B. J. Jones, and I. P. Coles, "The effect of tumour shrinkage on biological effectiveness of permanent brachytherapy implants," Br. J Radiol 67, 639-645 (1994).
24. K. E. Britton, S. J. Mather, and M. Granowska, "Radiolabeled monoclonal antibodies in oncology III Radioimmunotherapy," Nucl. Med. Commun. 12, 333-347 (1991).
25. S. Shen, G. L. DeNardo, S. J. DeNardo, Q. Salako, G. Morris, D. Banks, A. Yuan, and D. A. DeNardo, "Dosimetric evaluation of copper-64 in copper-67- 2IT-BAT-Lym-1 for radioimmunotherapy," J. Nucl. Med. 37, 146-150 (1996).